[go: up one dir, main page]

DK0886679T3 - Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner - Google Patents

Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner

Info

Publication number
DK0886679T3
DK0886679T3 DK97904453T DK97904453T DK0886679T3 DK 0886679 T3 DK0886679 T3 DK 0886679T3 DK 97904453 T DK97904453 T DK 97904453T DK 97904453 T DK97904453 T DK 97904453T DK 0886679 T3 DK0886679 T3 DK 0886679T3
Authority
DK
Denmark
Prior art keywords
vaccines
preparation
paracobal
foreign dna
containing foreign
Prior art date
Application number
DK97904453T
Other languages
English (en)
Inventor
Norbert Schmeer
Walter Strube
Mathias Buettner
Hans-Joachim Rziha
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19639601A external-priority patent/DE19639601A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK0886679T3 publication Critical patent/DK0886679T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK97904453T 1996-02-28 1997-02-17 Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner DK0886679T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607458 1996-02-28
DE19639601A DE19639601A1 (de) 1996-02-28 1996-09-26 Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PCT/EP1997/000729 WO1997032029A1 (de) 1996-02-28 1997-02-17 Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen

Publications (1)

Publication Number Publication Date
DK0886679T3 true DK0886679T3 (da) 2007-09-24

Family

ID=26023280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97904453T DK0886679T3 (da) 1996-02-28 1997-02-17 Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner

Country Status (19)

Country Link
US (1) US6365393B1 (da)
EP (1) EP0886679B1 (da)
JP (1) JP2000507092A (da)
CN (1) CN1217027A (da)
AT (1) ATE364090T1 (da)
AU (1) AU718141B2 (da)
BR (1) BR9707785A (da)
CA (1) CA2247336C (da)
DE (1) DE59712852D1 (da)
DK (1) DK0886679T3 (da)
ES (1) ES2287949T3 (da)
HU (1) HUP9901035A3 (da)
IL (1) IL125797A0 (da)
NO (1) NO983946L (da)
NZ (1) NZ331556A (da)
PL (1) PL190401B1 (da)
SK (1) SK120098A3 (da)
TR (1) TR199801702T2 (da)
WO (1) WO1997032029A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507449A (ja) * 1996-03-29 2000-06-20 ユニバーシティ オブ オタゴ パラポックスウイルスベクター
ES2389387T3 (es) * 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
ATE324902T1 (de) * 1998-11-02 2006-06-15 Ludwig Inst Cancer Res Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
PL366397A1 (pl) * 2000-07-11 2005-01-24 Bayer Aktiengesellschaft Zastosowanie szczepów owczego parapoksywirusa do wytwarzania przeciwwirusowych i przeciwnowotworowych środków farmaceutycznych
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
WO2003049683A2 (en) 2001-12-07 2003-06-19 Bayer Pharmacueticals Corporation Use of parapox b2l protein to treat cancer and modify immune responses
ATE442155T1 (de) * 2004-07-13 2009-09-15 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
CA2795308A1 (en) 2010-04-29 2011-11-03 Riemser Arzneimittel Ag Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
EP2571521A1 (en) * 2010-05-21 2013-03-27 Ah Usa 42 Llc Parapoxvirus vectors containing rabies virus antigen
MX2013000787A (es) * 2010-07-20 2013-08-08 Zoetis Llc Vectores de parapoxvirus.
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN115141773A (zh) 2015-08-14 2022-10-04 硕腾服务有限责任公司 牛支原体组合物
WO2017165366A1 (en) 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
BR112020018117A2 (pt) 2018-03-07 2020-12-22 Transgene Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1995030018A2 (en) * 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions

Also Published As

Publication number Publication date
WO1997032029A1 (de) 1997-09-04
NZ331556A (en) 2000-05-26
ES2287949T3 (es) 2007-12-16
AU718141B2 (en) 2000-04-06
HUP9901035A2 (hu) 1999-07-28
IL125797A0 (en) 1999-04-11
PL328870A1 (en) 1999-03-01
PL190401B1 (pl) 2005-12-30
AU1725797A (en) 1997-09-16
HUP9901035A3 (en) 2001-01-29
TR199801702T2 (xx) 1998-12-21
ATE364090T1 (de) 2007-06-15
DE59712852D1 (de) 2007-07-19
CA2247336A1 (en) 1997-09-04
BR9707785A (pt) 1999-07-27
NO983946D0 (no) 1998-08-27
EP0886679A1 (de) 1998-12-30
CA2247336C (en) 2008-06-17
EP0886679B1 (de) 2007-06-06
SK120098A3 (en) 1999-03-12
CN1217027A (zh) 1999-05-19
JP2000507092A (ja) 2000-06-13
US6365393B1 (en) 2002-04-02
NO983946L (no) 1998-10-22

Similar Documents

Publication Publication Date Title
DK0886679T3 (da) Parakoppevira indeholdende fremmed DNA, fremstilling heraf og deres anvendelse i vacciner
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
HK1046016B (zh) 疫苗中的重組脫氧核糖核酸膠原
DE69833649D1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE347599T1 (de) Tuberkulose impfstoff
DK79985A (da) Kloning af dna for protozoelle antigener og dets anvendelse
MX9708426A (es) Polipeptido hk2 de variante estable.
YU36698A (sh) Parapoks-virusi koji sadrže stranu dnk, njihovo dobijanje i njihova primena u vakcinama
DK0892054T3 (da) Clostridium perfringens-vaccine
IL131014A0 (en) Methods for cultivating cells and propagating viruses
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
WO1998024912A3 (en) Recombinant plague vaccine
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS